Tesaro's Zejula, or niraparib, has received FDA approval as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whose tumors have shrunk completely or in part because of platinum-based chemotherapy. The approval was based on a clinical study in which Zejula showed higher median progression-free survival of patients with BRCA mutation compared with placebo.
Gain the Most In Demand Skills in Health Care GW's School of Medicine Health Sciences connects you with leading authorities in policy and health care in Washington, D.C. With programs in clinical research, health care quality and regulatory affairs, you gain the most in demand skills. Learn More
Specialty pharmacies won't survive in a competitive market unless they avoid a series of errors that have caused some of their predecessors to fail. Those mistakes include competing against too broad a market segment, failing to progress with technology, neglecting social media and exaggerating capabilities.
First-attempt claims for PCSK9 inhibitor prescriptions were rejected about 80% of the time, according to an analysis of two large claims databases. The ultimate approval rate improved to 43% or better after followup with additional paperwork.
House Speaker Paul Ryan, R-Wis., told donors that Republicans will continue to pursue their health care agenda along with other policy priorities. "We're not going to just all of a sudden abandon health care and move on to the rest," Ryan said.
A supplemental new drug application has been submitted by Synergy Pharmaceuticals to the FDA for expanded use of Trulance, or plecanatide, as a treatment for adult patients who have irritable bowel syndrome with constipation. Trulance was approved in January to treat chronic idiopathic constipation in adults.
Novo Nordisk has received backing from the European Medicines Agency's Committee for Medicinal Products for Human Use for approval to market the hemophilia B drug Refixia, or nonacog beta pegol, in Europe. The opinion will be evaluated by the EMA.
Treatment for multiple sclerosis could progress from limiting relapses to repairing damage, thanks to a new study that reveals how the brain uses immune cells to repair myelin. The study, published in Nature Neuroscience, shows how proteins created by immune cells trigger the development of oligodendrocytes, which repair myelin.
The market for rheumatoid arthritis drugs in eight major markets will rise from $19.5 billion in 2015 to $28.5 billion in 2025, according to a report by GlobalData. The expected growth is based on multiple factors, including anticipation of increased RA prevalence, interleukin-6 inhibitor introductions, biosimilars for established biologics and early diagnosis and treatment.